CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 91 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03508830
NCT03508830Phase 3Completed

Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial - Liposomal Bupivacaine Versus Standard Bupivacaine

University of California, San Francisco·interventional·Posted Apr 26, 2018·Updated Jun 8, 2021

In Brief

A Phase 3 clinical trial evaluating Liposomal bupivacaine and Bupivacaine Injection for Thoracic Diseases and 2 related conditions. Completed, enrolled 91 participants across 1 site.

Detailed Summary

The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 26, 2018
Enrollment StartDec 30, 2018
Primary CompletionJan 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.2 years ago

Interventions

Liposomal bupivacainedrug

5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.

Bupivacaine Injectiondrug

5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.